The Ideal Therapy Must Be Def ined in Each Geographical Area: Experience with a Quadruple Therapy in Spain

Gomollón, Fernando; Ducóns, Julio; Gimeno, L.; Fuentes, Javier; García, Santiago López; Vera, Jesús; Montoro, Miguel

doi:10.1046/j.1523-5378.1998.08039.x

Cited by 10 publications

(3 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most commonly found quadruple regimen contained metronidazole, tetracycline, a gastric acid inhibitor, and a bismuth compound (GBMT) (Table 1). The GBMT regimen was used in 51 studies with a total of 3991 subjects and 85 treatment arms in five continents and 17 countries around the world including Canada, the United States, Russia, Hong Kong, Australia, India, New Zealand, Colombia, and nine countries in Europe 6–8, 10–12, 23–67 . The majority of the treatment arms used a PPI for gastric acid inhibition (85%), bismuth subsalicylate (40%) or colloidal bismuth subcitrate (36%), and came from articles published in peer‐reviewed journals (87%).…”

Section: Gastric Acid Inhibitor Bismuth Metronidazole and Tetracycmentioning

confidence: 99%

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

Fischbach

Zanten

Dickason

2004

Aliment Pharmacol Ther

186

155

View full text Add to dashboard Cite

SUMMARYBackground: Owing to rising drug-resistant Helicobacter pylori infections, currently recommended proton-pump inhibitor-based triple therapies are losing their efficacy, and regimens efficacious in the presence of drug resistance are needed. Aims: To summarize the efficacy, safety and adherence of first-line quadruple H. pylori therapies in adults. Methods: Meta-regression models identified factors explaining variation in the efficacy of first-line quadruple therapies from 145 treatment arms. Estimates of average efficacy were calculated within homogeneous groups. Results: Quadruple therapy containing a gastric acid inhibitor, bismuth, metronidazole and tetracycline was enhanced when omeprazole was included, treatment duration lasted 10-14 days, and when therapy took

show abstract

Section: Gastric Acid Inhibitor Bismuth Metronidazole and Tetracycmentioning

confidence: 99%

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

Fischbach

Zanten

Dickason

2004

Aliment Pharmacol Ther

186

155

View full text Add to dashboard Cite

show abstract

“…Data from randomized, controlled studies are very limited, to our knowledge. Quadruple therapy based on a combination of tetracycline, bismuth subcitrate, metronidazole, and a PPI has been proposed by experts as a reasonable choice in such patients, based on high efficacy when used as first‐line therapy [1,3–5]. However, few published studies do show data regarding the efficacy of this therapy as second‐line therapy [6].…”

mentioning

confidence: 99%

Quadruple Therapy Is Effective for Eradicating Helicobacter pylori After Failure of Triple Proton‐Pump Inhibitor–Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases

et al. 1999

Self Cite

View full text Add to dashboard Cite

show abstract

“…One week quadruple therapy of proton pump inhibitor + metronidazole + tetracycline + bismuth subcitrate was frequently studied, with the H. pylori eradication rate ranging from 86% to 100% 14 –18 . The eradication rate was similar if the same treatment was given for 4 days, but poor if the duration was further reduced to 2 days 14 , .…”

Section: Discussionmentioning

confidence: 99%

Three‐day lansoprazole quadruple therapy for Helicobacter pylori‐positive duodenal ulcers: a randomized controlled study

Wong

Wang

Wong

et al. 2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Aim: To compare the efficacy and tolerability of a 3‐day quadruple therapy with a standard 7‐day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers. Methods: Patients with H. pylori‐positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM‐7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB‐3). No pre‐ or post‐treatment acid suppression was used. Follow‐up endoscopy was performed at week 6. Results: A total of 118 patients were recruited. Sixty patients in the LCM‐7 group and 53 patients in the LCMB‐3 group returned for endoscopy. Intention‐to‐treat eradication rates were 87% and 86% (P=0.94) and per protocol eradication rates were 87% and 94% (P=0.29) in the LCM‐7 and LCMB‐3 groups, respectively. Per protocol and intention‐to‐treat ulcer healing rates were 98% and 98% in LCM‐7 and 100% and 91% in LCMB‐3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side‐effects was found in the LCMB‐3 group. Conclusion: The 3‐day quadruple therapy is highly effective, better tolerated and can be considered as a first‐line therapy in duodenal ulcer management.

show abstract

The Ideal Therapy Must Be Def ined in Each Geographical Area: Experience with a Quadruple Therapy in Spain

Abstract: Quadruple therapy with omeprazole, tetracycline, bismuth subcitrate and metronidazole achieves healing rates up to 95-100%. The 87.7% eradication rate obtained suggests that the regimen we used is a reasonable therapeutic alternative in our area.

Cited by 10 publications

References 24 publications

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

Quadruple Therapy Is Effective for Eradicating Helicobacter pylori After Failure of Triple Proton‐Pump Inhibitor–Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases

Three‐day lansoprazole quadruple therapy for Helicobacter pylori‐positive duodenal ulcers: a randomized controlled study

Contact Info

Product

Resources

About